通过快速混合深测序揭示大湖地区高频出现的青蒿素部分耐药突变
研究采用液滴血液保存与混合测序,对卢旺达及乌干达、坦桑尼亚、刚果民主共和国39家卫生机构的5465份疟疾阳性样本进行耐药突变频率评估,发现K13 561H和675V在卢旺达广泛分布,561H在坦桑尼亚多个站点高频出现, Uganda为1.6%,刚果民主共和国未检出561H但675V低频出现,其他耐药标记频率亦高。
要点
- 卢旺达90%站点检出K13 561H,平均频率19.0%(范围0%-54.5%)。
- 卢旺达65%站点检出K13 675V,平均频率5.0%(范围0%-35.5%)。
- 坦桑尼亚多个站点561H高频,乌干达561H频率1.6%,刚果民主共和国561H未检出但675V低频。
核心结论
- K13突变在该地区快速扩散,进一步危及疟疾控制工作,并可能促使伴侣药物耐药。
研究设计与样本
- 采用新型液滴血液保存与混合测序方法,对2022年5月至2023年3月期间从卢旺达及乌干达、坦桑尼亚、刚果民主共和国39家卫生机构采集的5465份疟疾阳性样本进行199个混合池的测序。
主要发现
- 卢旺达90%站点检出K13 561H,平均频率19.0%(范围0%-54.5%);65%站点检出675V,平均频率5.0%(范围0%-35.5%)。
- 坦桑尼亚多个站点561H高频出现;乌干达561H频率为1.6%;刚果民主共和国未检出561H,但675V低频出现。
- 候选突变441L、449A和469F与已验证突变共现,提示其在相同压力下产生。
- P falciparum multidrug resistance protein 1 N86频率98.0%(范围63.3%-100%),184F频率47.0%(范围0%-94.3%);P falciparum chloroquine resistance transporter 76T频率14.7%(范围0%-58.6%)。
- 磺胺多辛-乙胺嘧啶相关突变显示高频率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In Africa, the first Plasmodium falciparum artemisinin partial resistance mutation was Kelch13 (K13) 561H, detected and validated at appreciable frequency in Rwanda in 2014. Surveillance to better define the extent of the emergence in Rwanda and neighboring countries is critical. METHODS: We used novel liquid blood drop preservation with pooled sequencing to provide cost-effective rapid assessment of resistance mutation frequencies at multiple collection sites across Rwanda and neighboring regions in Uganda, Tanzania, and the Democratic Republic of the Congo. Malaria-positive samples (N = 5465) from 39 health facilities collected between May 2022 and March 2023 were sequenced in 199 pools. RESULTS: In Rwanda, K13 561H and 675V were detected in 90% and 65% of sites, with an average frequency of 19.0% (range, 0%-54.5%) and 5.0% (0%-35.5%), respectively. In Tanzania, 561H had high frequency in multiple sites. 561H appeared at 1.6% in Uganda. 561H was absent from the Democratic Republic of the Congo, although 675V was seen at low frequency. Concerningly, candidate mutations were observed: 441L, 449A, and 469F co-occurred with validated mutations, suggesting that they are arising under the same pressures. Other markers for decreased susceptibility to artemether-lumefantrine are common: P falciparum multidrug resistance protein 1 N86 at 98.0% (range, 63.3%-100%) and 184F at 47.0% (0%-94.3%) and P falciparum chloroquine resistance transporter 76T at 14.7% (0%-58.6%). Additionally, sulfadoxine-pyrimethamine-associated mutations show high frequencies. CONCLUSIONS: K13 mutations are rapidly expanding in the region, further endangering control efforts with the potential of engendering partner drug resistance.
引用
- Wernsman Young N, Gashema P, Giesbrecht D, et al. High Frequency of Artemisinin Partial Resistance Mutations in the Great Lakes Region Revealed Through Rapid Pooled Deep Sequencing. J Infect Dis. 2025. PMID: 39367758. doi:10.1093/infdis/jiae475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。